IL99924A - Derivatives of structurally modified vip and pharmaceutical compositions containing them - Google Patents

Derivatives of structurally modified vip and pharmaceutical compositions containing them

Info

Publication number: IL99924A
Authority: IL; Israel
Prior art keywords: vip; conjugate according; conjugate; stearoyl; pharmaceutical composition
Prior art date: 1991-10-31

Application number

IL9992491A

Other languages

English (en)

Other versions

IL99924A0 (en

Inventor

Matityahu Fridkin

Illana Gozes

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-10-31

Filing date

1991-10-31

Publication date

1995-12-31

1991-10-31 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

1991-10-31 Priority to IL9992491A priority Critical patent/IL99924A/en

1992-08-18 Publication of IL99924A0 publication Critical patent/IL99924A0/xx

1992-10-26 Priority to AT92118271T priority patent/ATE174932T1/de

1992-10-26 Priority to DE69227979T priority patent/DE69227979T2/de

1992-10-26 Priority to EP92118271A priority patent/EP0540969B1/fr

1992-10-29 Priority to TW081108625A priority patent/TW224470B/zh

1992-10-30 Priority to KR1019920020187A priority patent/KR100240434B1/ko

1992-11-02 Priority to JP33485092A priority patent/JP3311800B2/ja

1993-01-15 Priority to CN93101710A priority patent/CN1060178C/zh

1995-12-31 Publication of IL99924A publication Critical patent/IL99924A/en

1997-07-21 Priority to US08/897,624 priority patent/US5998368A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 12
VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims abstract description 41
239000000203 mixture Substances 0.000 claims abstract description 32
102000055135 Vasoactive Intestinal Peptide Human genes 0.000 claims abstract description 29
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims abstract description 29
201000001881 impotence Diseases 0.000 claims abstract description 19
150000001413 amino acids Chemical group 0.000 claims abstract description 14
125000000539 amino acid group Chemical group 0.000 claims abstract description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims description 10
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
239000004474 valine Substances 0.000 claims description 7
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
235000011187 glycerol Nutrition 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
239000004480 active ingredient Substances 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
229940087068 glyceryl caprylate Drugs 0.000 claims description 5
239000000314 lubricant Substances 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims description 4
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 4
229960003711 glyceryl trinitrate Drugs 0.000 claims description 4
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
229930182817 methionine Natural products 0.000 claims description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 claims description 2
NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 claims description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
125000001589 carboacyl group Chemical group 0.000 claims description 2
125000000524 functional group Chemical group 0.000 claims description 2
125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
229920006395 saturated elastomer Polymers 0.000 claims description 2
238000013268 sustained release Methods 0.000 claims description 2
239000012730 sustained-release form Substances 0.000 claims description 2
VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 claims description 2
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
108090000765 processed proteins & peptides Proteins 0.000 abstract description 16
150000001875 compounds Chemical class 0.000 abstract description 14
238000000034 method Methods 0.000 abstract description 12
239000012634 fragment Substances 0.000 abstract description 3
101000953492 Homo sapiens Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 1 Proteins 0.000 abstract 1
102100037739 Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 1 Human genes 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
238000002474 experimental method Methods 0.000 description 17
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
239000002674 ointment Substances 0.000 description 15
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
229920000642 polymer Polymers 0.000 description 11
-1 stearoyl VIP Chemical compound 0.000 description 11
241001465754 Metazoa Species 0.000 description 10
229940024606 amino acid Drugs 0.000 description 10
229940079593 drug Drugs 0.000 description 10
239000003814 drug Substances 0.000 description 10
239000011347 resin Substances 0.000 description 10
229920005989 resin Polymers 0.000 description 10
238000005859 coupling reaction Methods 0.000 description 9
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
241000700159 Rattus Species 0.000 description 8
230000008878 coupling Effects 0.000 description 8
238000010168 coupling process Methods 0.000 description 8
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 8
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 7
230000035515 penetration Effects 0.000 description 7
210000003899 penis Anatomy 0.000 description 7
239000000047 product Substances 0.000 description 7
230000001568 sexual effect Effects 0.000 description 7
238000012360 testing method Methods 0.000 description 7
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 6
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
230000018052 penile erection Effects 0.000 description 6
230000011514 reflex Effects 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
201000011264 priapism Diseases 0.000 description 5
239000002904 solvent Substances 0.000 description 5
229930008281 A03AD01 - Papaverine Natural products 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
239000000969 carrier Substances 0.000 description 4
235000019441 ethanol Nutrition 0.000 description 4
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 4
229960001789 papaverine Drugs 0.000 description 4
125000006239 protecting group Chemical group 0.000 description 4
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
FYYSQDHBALBGHX-YFKPBYRVSA-N N(alpha)-t-butoxycarbonyl-L-asparagine Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC(N)=O FYYSQDHBALBGHX-YFKPBYRVSA-N 0.000 description 3
239000000006 Nitroglycerin Substances 0.000 description 3
QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000012043 crude product Substances 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
SHDMMLFAFLZUEV-UHFFFAOYSA-N n-methyl-1,1-diphenylmethanamine Chemical compound C=1C=CC=CC=1C(NC)C1=CC=CC=C1 SHDMMLFAFLZUEV-UHFFFAOYSA-N 0.000 description 3
229960003418 phenoxybenzamine Drugs 0.000 description 3
230000009329 sexual behaviour Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
239000002262 Schiff base Substances 0.000 description 2
150000004753 Schiff bases Chemical class 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
150000003862 amino acid derivatives Chemical class 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
210000005226 corpus cavernosum Anatomy 0.000 description 2
210000005225 erectile tissue Anatomy 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
238000011068 loading method Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
230000008569 process Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000006722 reduction reaction Methods 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
WLHCBQAPPJAULW-UHFFFAOYSA-N 4-methylbenzenethiol Chemical compound CC1=CC=C(S)C=C1 WLHCBQAPPJAULW-UHFFFAOYSA-N 0.000 description 1
206010006784 Burning sensation Diseases 0.000 description 1
208000010228 Erectile Dysfunction Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
238000007098 aminolysis reaction Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000002585 base Substances 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000007689 inspection Methods 0.000 description 1
239000007926 intracavernous injection Substances 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000000955 neuroendocrine Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
OENLEHTYJXMVBG-UHFFFAOYSA-N pyridine;hydrate Chemical compound [OH-].C1=CC=[NH+]C=C1 OENLEHTYJXMVBG-UHFFFAOYSA-N 0.000 description 1
239000012857 radioactive material Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012827 research and development Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000036259 sexual stimuli Effects 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000000050 smooth muscle relaxant Substances 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012956 testing procedure Methods 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
238000012384 transportation and delivery Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/04—Preparations for care of the skin for chemically tanning the skin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Birds (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gynecology & Obstetrics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL9992491A 1991-10-31 1991-10-31 Derivatives of structurally modified vip and pharmaceutical compositions containing them IL99924A (en)

Priority Applications (9)

Application Number	Priority Date	Filing Date	Title
IL9992491A IL99924A (en)	1991-10-31	1991-10-31	Derivatives of structurally modified vip and pharmaceutical compositions containing them
AT92118271T ATE174932T1 (de)	1991-10-31	1992-10-26	Modifizierte vip-derivate und sie enthaltende pharmazeutische zusammensetzungen
DE69227979T DE69227979T2 (de)	1991-10-31	1992-10-26	Modifizierte VIP-Derivate und sie enthaltende pharmazeutische Zusammensetzungen
EP92118271A EP0540969B1 (fr)	1991-10-31	1992-10-26	Dérivés de VIP modifiés et leurs compositions pharmaceutiques les contenants
TW081108625A TW224470B (fr)	1991-10-31	1992-10-29
KR1019920020187A KR100240434B1 (ko)	1991-10-31	1992-10-30	구조적으로 변형된 혈관작용성 소장 펩티드(vip)의 유도체 및 이를 함유한 제약 조성물
JP33485092A JP3311800B2 (ja)	1991-10-31	1992-11-02	血管作動性小腸ペプチドの新規誘導体
CN93101710A CN1060178C (zh)	1991-10-31	1993-01-15	新的结构改性的活性肠肽衍生物、其药物组合物及其治疗男性阳痿的应用
US08/897,624 US5998368A (en)	1991-10-31	1997-07-21	Derivatives of structurally modified VIP and pharmaceutical compositions containing them

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IL9992491A IL99924A (en)	1991-10-31	1991-10-31	Derivatives of structurally modified vip and pharmaceutical compositions containing them
CN93101710A CN1060178C (zh)	1991-10-31	1993-01-15	新的结构改性的活性肠肽衍生物、其药物组合物及其治疗男性阳痿的应用

Publications (2)

Publication Number	Publication Date
IL99924A0 IL99924A0 (en)	1992-08-18
IL99924A true IL99924A (en)	1995-12-31

Family

ID=36792814

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9992491A IL99924A (en)	1991-10-31	1991-10-31	Derivatives of structurally modified vip and pharmaceutical compositions containing them

Country Status (7)

Country	Link
EP (1)	EP0540969B1 (fr)
JP (1)	JP3311800B2 (fr)
KR (1)	KR100240434B1 (fr)
CN (1)	CN1060178C (fr)
AT (1)	ATE174932T1 (fr)
DE (1)	DE69227979T2 (fr)
IL (1)	IL99924A (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5447912A (en) *	1989-09-18	1995-09-05	Senetek, Plc	Erection-inducing methods and compositions
IL105061A (en) *	1993-03-16	2000-11-21	Yeda Res & Dev	Pharmaceutical compositions for the treatment of neurodegenerative diseases comprising VIP analogues and fragments thereof
US5565424A (en) *	1994-02-07	1996-10-15	Ramot - University Authority For Applied Research And Industrial Development Ltd.	Superactive VIP antagonists
IL118003A0 (en)	1996-04-23	1996-08-04	Yeda Res & Dev	Novel vip fragments and pharmaceutical compositions comprising them
IL136631A0 (en) *	2000-06-07	2001-06-14	Yeda Res & Dev	Vip-related peptides for treatment of skin disordes
FR2854897B1 (fr) *	2003-05-12	2007-05-04	Sederma Sa	Compositions cosmetiques ou dermopharmaceutiques pour reduire les signes du vieillissement cutane.
US8841255B2 (en)	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
CN105727261A (zh)	2008-06-27	2016-07-06	杜克大学	包含弹性蛋白样肽的治疗剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4605641A (en) *	1984-10-09	1986-08-12	Hoffmann-La Roche Inc.	Synthetic vasoactive intestinal peptide analogs
SE8702520D0 (sv) *	1987-06-16	1987-06-16	Kabigen Ab	Mammal intestine hormone precursor
IL87055A (en) *	1988-07-08	1994-06-24	Illana Gozes	Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
DK0463450T3 (da) *	1990-06-26	1994-06-27	Sanwa Kagaku Kenkyusho Co	Vasoaktive intestinale polypeptid-analoger og udnyttelsen heraf

1991
- 1991-10-31 IL IL9992491A patent/IL99924A/en not_active IP Right Cessation
1992
- 1992-10-26 EP EP92118271A patent/EP0540969B1/fr not_active Expired - Lifetime
- 1992-10-26 AT AT92118271T patent/ATE174932T1/de not_active IP Right Cessation
- 1992-10-26 DE DE69227979T patent/DE69227979T2/de not_active Expired - Fee Related
- 1992-10-30 KR KR1019920020187A patent/KR100240434B1/ko not_active Expired - Fee Related
- 1992-11-02 JP JP33485092A patent/JP3311800B2/ja not_active Expired - Fee Related
1993
- 1993-01-15 CN CN93101710A patent/CN1060178C/zh not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ATE174932T1 (de)	1999-01-15
EP0540969A3 (fr)	1994-08-03
EP0540969B1 (fr)	1998-12-23
DE69227979T2 (de)	1999-07-01
JP3311800B2 (ja)	2002-08-05
CN1089950A (zh)	1994-07-27
KR100240434B1 (ko)	2000-01-15
EP0540969A2 (fr)	1993-05-12
DE69227979D1 (de)	1999-02-04
IL99924A0 (en)	1992-08-18
JPH06206898A (ja)	1994-07-26
CN1060178C (zh)	2001-01-03

Legal Events

Date	Code	Title
1996-06-18	FF	Patent granted
1998-04-05	KB	Patent renewed
2002-02-10	KB	Patent renewed
2006-08-01	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
US5147855A (en)	1992-09-15	Conjugates of vip and active fragments thereof with hydrophobic moieties and topical compositions for male impotence
US6239107B1 (en)	2001-05-29	Conjugates of lipophilic moieties and fragments of vasoactive intestinal peptide (VIP)
US6051555A (en)	2000-04-18	Stimulating sexual response in females
Rivier et al.	2002	Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists
CN103189389B (zh)	2017-08-11	新的glp‑ⅰ类似物及其制备方法和用途
Gozes et al.	1994	Stearyl-norleucine-vasoactive intestinal peptide (VIP): a novel VIP analog for noninvasive impotence treatment
CA2218173A1 (fr)	1996-10-17	Analogues du facteur liberant l'hormone de croissance
RU2335506C2 (ru)	2008-10-10	Пептидные аналоги gh-rh с антагонистическим действием, способ снижения уровня gh, способ снижения уровня igf-i и igf-ii, применение для ингибирования роста раковых клеток, фармакологически приемлемая композиция (варианты)
Gozes et al.	1992	A fatty neuropeptide. Potential drug for noninvasive impotence treatment in a rat model.
US5646301A (en)	1997-07-08	D-2-alkyl tryptophan compounds
HUT50487A (en)	1990-02-28	Process for production of peptides
EP0540969B1 (fr)	1998-12-23	Dérivés de VIP modifiés et leurs compositions pharmaceutiques les contenants
US5998368A (en)	1999-12-07	Derivatives of structurally modified VIP and pharmaceutical compositions containing them
WO2000031136A1 (fr)	2000-06-02	Analogues antagonistes de gh-rh inhibant igf-i et igf-ii
JPH05503103A (ja)	1993-05-27	障害を受けた組織における血管漏洩を抑制する抗炎症ペプチド及びその組織の治療方法
CZ284168B6 (cs)	1998-09-16	Způsob navrhování a syntetizace antagonistů LHRH
CA2527830A1 (fr)	2004-12-23	Compositions vaccinales therapeutiques servant a traiter le diabete de type 1
CA2158425C (fr)	2003-01-28	Diagnostic et traitement pour les dysfonctions erectiles
EP0383856A1 (fr)	1990-08-29	Utilisation des peptides pour empecher le blocage de vaisseaux sanguins.
US20030036514A1 (en)	2003-02-20	Compositions and methods for the diagnosis and treatment of psychogenic erectile dysfunction
EP3638778A1 (fr)	2020-04-22	Peptides pour le traitement du diabète de type 2